MarketExclusive.com reports today that Neuralstem, Inc. (NYSE MKT: CUR)(CUR), an adult stem cell developer, published a blog post entitled “The accident was a horrible thing - but that horrible thing made Chris, at the end of his life, Superman. It's a happy irony if there is such a thing. I'm proud to have known him,” on the Company’s website (http://www.neuralstem.com/neuralstem-ceo-blog/147-spinal-cord-injury-trial), which was republished on TheChairmansBlog.com.
Neuralstem’s President and CEO, Richard Garr, reflected on the Company’s recently FDA approved Spinal Cord Injury Trial. He believes the FDA approval “shows a growing comfort level with [Neuralstem’s] spinal cord cells, and [the Company’s] route of administration.”
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
MarketExclusive.com provides insights specifically for investors, business professionals, and entrepreneurs. It also aims to provide premium investment newsletters for serious investors in stocks, commodities, and other publicly traded vehicles.